A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Clinical trial NCT03652064 · COMPLETED

Trial details

NCT number: NCT03652064
Sponsor: Janssen Research & Development, LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2018-11-06
Primary completion: 2024-05-07
Enrollment: 395

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.